Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Open Access
- 1 February 2015
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 10 (2), 232-236
- https://doi.org/10.1097/jto.0000000000000455
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy eraLung Cancer, 2012
- ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosisLung Cancer, 2012
- Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain RadiotherapyJournal of Thoracic Oncology, 2012
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Leptomeningeal metastases in the MRI eraNeurology, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasisAnnals of Neurology, 1995
- Malignant cells in cerebrospinal fluid (CSF)Neurology, 1979